Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile – VORONOI

Skip to content

CAREERS
INVESTORS
NEWSROOM
LANGUAGE
- Korean
- English

COMPANY
- About VORONOI
- Our work
SCIENCE
- Pipeline
- R&D Platform
PEOPLE
- Meet the experts
- Scientific Advisory Board
CAREERS
INVESTORS
NEWS
KOREAN
ENGLISH

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

admin2023-10-23T18:15:54+00:00

032-830-4855 / contact@voronoi.io
S 18th F,Songdogwahak-ro 32(ITcenter), Yeonsu-gu, Incheon, Republic of Korea
Copyrightⓒ Voronoi All Rights reserved.